A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

Trial Profile

A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Metadoxine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Alcobra
  • Most Recent Events

    • 12 Feb 2015 According to a media release, Alcobra is scheduled to meet with the FDA in the first quarter of 2015 to discuss the results of its first phase III study reported in Oct 2014.
    • 17 Nov 2014 Status changed from active, no longer recruiting to completed, according to an Alcobra media release.
    • 17 Nov 2014 Results published in an Alcobra media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top